EPHX2 and neoplasm: Mechanistically, tumors upregulate LPA signaling through a combination of increased ATX production either by the cancer cells themselves or tumor stroma, autocrine overexpression of the LPAR receptors, or downregulation of total tumor lipid phosphate phosphatase (LPP) activity, which degrades LPA into monoacylglycerol [4].